Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | AGXT | P21549 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13033029 | 0.89 | IDO1 (0.48) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL1162782 | 0.85 | TSHR (0.48) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL7712856 | 0.85 | TSHR (0.48) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL6132100 | 0.85 | IDO1 (0.56) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL2836727 | 0.80 | TSHR (0.43) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL30186261 | 0.79 | TSHR (0.52) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL907608 | 0.79 | TSHR (0.52) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL1690445 | 0.79 | TSHR (0.52) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL1581064 | 0.79 | TSHR (0.41) | TSHRIDO1AGXTALDH1A1CA1 | |
| SCHEMBL15740560 | 0.76 | IDO1 (0.54) | IDO1ALDH1A1CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024254448-A2 | BORONATE PRODRUG NANOFORMULATIONS IN DISEASE TREATMENTS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-12-12 | — | — | WO | claimed |
| US-20120053427-A1 | OPTICAL SENSOR CONFIGURATION AND METHODS FOR MONITORING GLUCOSE ACTIVITY IN INTERSTITIAL FLUID | GLUMETRICS, INC. (US) | 2012-03-01 | — | — | US | claimed |
| US-20100226597-A1 | BORTEZOMIB AND PROCESS FOR PRODUCING SAME | DR. REDDY'S LABORATORIES LIMITED (IN) | 2010-09-09 | — | — | US | claimed |
| EP-2185159-A2 | BORTEZOMIB AND PROCESS FOR PRODUCING SAME | Dr. Reddy's Laboratories, Ltd. (IN) | 2010-05-19 | — | — | EP | claimed |
| WO-2009036281-A2 | BORTEZOMIB AND PROCESS FOR PRODUCING SAME | DR. REDDY'S LABORATORIES LTD. (IN) | 2009-03-19 | — | — | WO | claimed |
| US-6653141-B2 | In vitro detection of polyhydroxyl-substituted organic molecules; obtain sample, incubate in fluorescent dye exposure to excitation light detect and measure signal | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-11-25 | — | — | US | claimed |
| US-20020106810-A1 | Polyhydroxyl-substituted organic molecule sensing optical in vitro method utilizing a boronic acid adduct and the device thereof | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2002-08-08 | — | — | US | claimed |
| EP-0765331-B1 | OXABOROLES AND SALTS THEREOF, AND THEIR USE AS BIOCIDES | AVECIA LTD (GB) | 2000-08-09 | — | — | EP | claimed |
| US-5880188-A | PROTECTING MEDIUM SUSCEPTIBLE TO MICROBIAL ATTACK BY TREATING WITH SPECIFIED OXABOROLE COMPOUND | ZENECA LIMITED (GB) | 1999-03-09 | — | — | US | claimed |
| EP-0765331-A1 | OXABOROLES AND SALTS THEREOF, AND THEIR USE AS BIOCIDES | ZENECA LIMITED (GB) | 1997-04-02 | — | — | EP | claimed |
| WO-1995033754-A1 | OXABOROLES AND SALTS THEREOF, AND THEIR USE AS BIOCIDES | ZENECA LIMITED (GB) | 1995-12-14 | — | — | WO | claimed |
| EP-0607334-A1 | CYCLIC UREAS AND ANALOGUES USEFUL AS RETROVIRAL PROTEASE INHIBITIORS. | DU PONT MERCK PHARMA (US) | 1994-07-27 | — | — | EP | claimed |
| EP-3609891-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA CELLULAR THERAPIES INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12428403-B2 | N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-09-30 | — | — | US | disclosed |
| US-20250101022-A1 | PROCESS FOR PREPARING INTERMEDIATES FOR 1-(4-FLUOROPHENYL)-4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3’,4’:4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)BUTAN-1-ONE | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-03-27 | — | — | US | disclosed |
| WO-2024254448-A2 | BORONATE PRODRUG NANOFORMULATIONS IN DISEASE TREATMENTS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-12-12 | — | — | WO | disclosed |
| EP-0796085-A1 | SOLUBILISATION AIDS FOR HYDROPHILIC MACROMOLECULES | CORTECS LIMITED (GB) | 1997-09-24 | — | — | EP | disclosed |
| WO-1997012853-A1 | DIMER-SELECTIVE RXR MODULATORS AND METHODS FOR THEIR USE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-04-10 | — | — | WO | disclosed |
| WO-1996017593-A1 | SOLUBILISATION AIDS FOR HYDROPHILIC MACROMOLECULES | CORTECS LIMITED (GB) | 1996-06-13 | — | — | WO | disclosed |
| US-4847295-A | ANTITUMOR AGENTS | FARMITALIA CARLO ERBA S.R.L. (IT) | 1989-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101022-A1 | PROCESS FOR PREPARING INTERMEDIATES FOR 1-(4-FLUOROPHENYL)-4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3’,4’:4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)BUTAN-1-ONE | CYP1B1, CYP4B1, CBR1 | TSHR 2882/4885IDO1 151/4885AGXT 3408/4885 |
| US-12428403-B2 | N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists | SSTR4, SSTR3, SSTR1 | TSHR 31/4885IDO1 2861/4885AGXT 3088/4885 |
| US-20100226597-A1 | BORTEZOMIB AND PROCESS FOR PRODUCING SAME | PSMC1, PSMB4, PSMB1 | TSHR 4307/4885IDO1 4832/4885AGXT 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.